Fox, Susan H.
Susan H Fox
VIAF ID: 207887174 (Personal)
Permalink: http://viaf.org/viaf/207887174
Preferred Forms
- 100 1 _ ‡a Fox, Susan H
-
-
-
-
- 100 1 _ ‡a Fox, Susan H.
-
-
- 100 1 _ ‡a Fox, Susan H.
- 100 0 _ ‡a Susan H Fox
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Clinimetric testing of the comprehensive cervical dystonia rating scale | |
A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale | |
Dihydropyridine calcium channel blockers and the progression of parkinsonism. | |
l-Dopa-induced dyskinesia-clinical presentation, genetics, and treatment | |
Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease | |
The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. | |
Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia | |
Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. | |
Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. | |
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. | |
Helicobacter pylori infection is associated with worse severity of Parkinson's disease | |
The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. | |
Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease | |
Improvement of apathy after levofloxacin treatment: an N-of-1 study. | |
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. | |
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease | |
Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management | |
Levodopa-related motor complications--phenomenology | |
The long-term outcome of orthostatic tremor. | |
The meaning of a "hippo" response on the Montreal Cognitive Assessment in Parkinson's disease | |
Medication-related impulse control and repetitive behaviors in Parkinson disease | |
Monoamine reuptake inhibitors in Parkinson's disease | |
Movement disorders | |
Mutation analysis of CHCHD10 in different neurodegenerative diseases | |
Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome | |
New insights into the organization of the basal ganglia | |
New methods of preventing neurodegeneration? Lessons from prion diseases | |
The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease | |
Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials | |
Overview of the extranigral aspects of Parkinson disease | |
Parkinson's disease : current and future therapeutics and clinical trials | |
Parkinson's disease / edited by Néstor Gálvez-Jiménez [et al.]. - Cambridge, 2016. | |
The pill questionnaire in a nondemented Parkinson's disease population. | |
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study. | |
Psychiatric comorbidities in dystonia: emerging concepts | |
Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management | |
Pure cerebello-olivary degeneration of Marie, Foix, and Alajouanine presenting with progressive cerebellar ataxia, cognitive decline, and chorea. | |
Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia | |
Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. | |
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study | |
Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update | |
Serotonin and Parkinson's disease: On movement, mood, and madness | |
Small intestinal bacterial overgrowth in Parkinson's disease. | |
Striatal histone modifications in models of levodopa-induced dyskinesia | |
Subthalamic nucleus and striatum: the red and green signals to regulate the traffic of basal ganglia circuitry. | |
Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. | |
Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death | |
Treating the Motor Symptoms of Parkinson Disease | |
Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease | |
Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease | |
Understanding conversion disorders: back to Freud's theory. | |
Update in therapeutic strategies for Parkinson's disease. | |
Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque | |
Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias | |
Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold? | |
Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation | |
Wilson disease: Canadian perspectives on presentation and outcomes from an adult ambulatory setting | |
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |